Author: Leah Kosyakovsky

TEAMMATE Trial: Everolimus with Low-Dose Tacrolimus to Prevent Rejection in Children after Cardiac Transplantation
AHA 2023, Heart Failure, Heart trasnplant, News

TEAMMATE Trial: Everolimus with Low-Dose Tacrolimus to Prevent Rejection in Children after Cardiac Transplantation

Key Points This was the first randomized trial to evaluate the safety and efficacy of everolimus and low-dose tacrolimus in pediatric heart transplant recipients.... Read more.
Percutaneous Coronary Intervention Improved Symptoms in Stable Angina: ORBITA-2 trial
AHA 2023, Interventional Cardiology, News

Percutaneous Coronary Intervention Improved Symptoms in Stable Angina: ORBITA-2 trial

Key points: PCI is often performed for chronic stable angina, but current evidence is unclear to what extent the benefit is physiologic vs placebo This trial compared... Read more.
MINT Trial – In Patients with MI and Anemia, Liberal Blood Transfusion not Significantly Different to Restrictive Strategy in Reducing Death or MI
AHA 2023, News

MINT Trial – In Patients with MI and Anemia, Liberal Blood Transfusion not Significantly Different to Restrictive Strategy in Reducing Death or MI

Key Points Anemia is common among individuals with acute myocardial infarction, however, transfusion thresholds and targets remain uncertain. The MINT trial randomized... Read more.
DAPA-MI: Dapagliflozin improves clinical and cardiometabolic outcomes in post-AMI patients with impaired LV function versus placebo 
AHA 2023, News

DAPA-MI: Dapagliflozin improves clinical and cardiometabolic outcomes in post-AMI patients with impaired LV function versus placebo 

Key Points  This trial of patients with acute myocardial infarction (AMI) and impaired left ventricular (LV) systolic function found that dapagliflozin significantly... Read more.
SELECT TRIAL: Semaglutide reduces cardiovascular events among overweight or obese patients with cardiovascular disease in the absence of diabetes 
AHA 2023

SELECT TRIAL: Semaglutide reduces cardiovascular events among overweight or obese patients with cardiovascular disease in the absence of diabetes 

Key Points:  Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has previously been shown to reduce body weight among overweight or obese individuals. However,... Read more.
PUSH-AHF: Natriuresis-guided diuresis approach increases natriuresis and diuresis without improving all-cause mortality or HF hospitalization
ESC 2023, News

PUSH-AHF: Natriuresis-guided diuresis approach increases natriuresis and diuresis without improving all-cause mortality or HF hospitalization

Key Points: Diuretic requirement Is a major contributor to hospital length-of-stay for HF admissions, but the optimal strategy of diuretic optimization has not yet... Read more.